Spire Healthcare Group (LON:SPI) Trading Down 18.1% on Analyst Downgrade

Spire Healthcare Group plc (LON:SPI) fell 18.1% on Thursday after Deutsche Bank Aktiengesellschaft lowered their price target on the stock from GBX 320 to GBX 300. Deutsche Bank Aktiengesellschaft currently has a buy rating on the stock. Spire Healthcare Group traded as low as GBX 169 ($2.18) and last traded at GBX 183.95 ($2.38). 8,024,729 shares were traded during mid-day trading, an increase of 1,005% from the average session volume of 726,218 shares. The stock had previously closed at GBX 224.50 ($2.90).

Spire Healthcare Group Price Performance

The company has a quick ratio of 0.74, a current ratio of 0.70 and a debt-to-equity ratio of 62.25. The stock has a market cap of £711.58 million, a price-to-earnings ratio of 25.22, a price-to-earnings-growth ratio of 1.06 and a beta of 0.96. The company’s 50-day moving average is GBX 227.28 and its 200-day moving average is GBX 229.74.

Spire Healthcare Group (LON:SPI) last posted its quarterly earnings results on Thursday, March 6th. The company reported GBX 8.80 ($0.11) earnings per share (EPS) for the quarter. Spire Healthcare Group had a net margin of 1.96% and a return on equity of 3.82%. Equities research analysts expect that Spire Healthcare Group plc will post 15.6634747 earnings per share for the current fiscal year.

About Spire Healthcare Group

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.